<DOC>
	<DOCNO>NCT01641809</DOCNO>
	<brief_summary>The study design select dose GSK1265744 primarily basis antiviral activity tolerability HIV-1 infect , antiretroviral naive subject . This study consist two part : Induction Phase : Approximately 200 subject randomize ( 50 subject 4 treatment arm ) . The Induction Phase consist 24 week dose-ranging evaluation GSK1265744 blind dose 10 mg , 30 mg 60 mg once-daily control arm open-label efavirenz ( EFV ) 600 mg daily . The background dual nucleoside reverse transcriptase inhibitor ( NRTI ) antiretroviral therapy ( ART ) arm either abacavir/lamivudine ( ABC/3TC ) tenofovir/emtricitabine ( TDF/FTC ) select Investigator . Subjects randomize GSK1265744 contain arm , successfully complete 24 week study demonstrate virologic suppression ( defined plasma HIV-1 ribonucleic acid [ RNA ] &lt; 50 copy per milliliter [ c/mL ] Week 24 , sign virologic rebound ) become eligible Maintenance Phase study . Maintenance Phase : The background NRTIs discontinue subject continue randomize dose GSK1265744 combination rilpivirine ( RPV ) 25 mg once-daily additional 72 week . The Maintenance phase evaluate ability two drug ART regimen maintain virologic suppression Week 48 , Week 72 Week 96 . Subjects randomize EFV arm continue randomize regimen Week 96 . After completion maintenance phase , subject could enroll Open-Label Phase continue GSK1265744 + RPV treatment long continue derive clinical benefit locally approve commercially available .</brief_summary>
	<brief_title>Dose Ranging Study GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors Induction Human Immunodeficiency Virus-1 ( HIV-1 ) Virologic Suppression Followed Virologic Suppression Maintenance GSK1265744 Plus Rilpivirine</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infect male female subject &gt; = 18 year age Screening plasma HIV1 RNA &gt; =1000 c/mL CD4+ cell count &gt; =200 cells/millimeter ( mm ) ^3 ARTnaive define = &lt; 10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection Female subject child bear potential eligible enter pregnant willing use protocolspecified method contraception prevent pregnancy study Any evidence screen active Centers Disease Prevention Control ( CDC ) Category C disease Treatment HIV1 immunotherapeutic vaccine within 90 day Screening History ongoing clinically relevant hepatitis within previous 6 month , subject moderate severe hepatic impairment exclude Women breastfeed Subject , investigator 's judgment , pose significant suicide risk Any clinically significant find screen baseline electrocardiograph ( ECG ) The presence specific laboratory abnormality Screening History cardiac disease Clinically relevant pancreatitis Subjects unlikely complete dosing schedule due preexist physical mental condition Any condition impairs absorption , distribution , metabolism excretion investigational product Any evidence primary resistance base upon presence major resistance associate mutation Screening HIV genotype , historical genotype Treatment protocolspecified excluded medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV -1</keyword>
	<keyword>GSK1265744</keyword>
	<keyword>maintenance phase</keyword>
	<keyword>dose selection</keyword>
</DOC>